All data are based on the daily closing price as of November 13, 2026
p

PharmaEngine

4162.TWO
1.66 USD
0.05
+3.11%

Overview

Last close
1.66 usd
Market cap
238.30M usd
52 week high
3.08 usd
52 week low
1.59 usd
Target price
3.65 usd

Valuation

P/E
14.1192
Forward P/E
6.2735
Price/Sales
7.639
Price/Book Value
1.551
Enterprise Value
78.50M usd
EV/Revenue
2.518
EV/EBITDA
3.9244

Key financials

Revenue TTM
31.18M usd
Gross Profit TTM
29.26M usd
EBITDA TTM
14.81M usd
Earnings per Share
0.12 usd
Dividend
N/A usd
Total assets
170.54M usd
Net debt
N/A usd

About

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
  • Symbol
    4162.TWO
  • Exchange
    TWO
  • Isin
    TW0004162003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hong-Ren Wang Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.pharmaengine.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top